Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Dent

Showing results (71-80 of 395) with videos related to

Pageof 40
Sort By:
Oncotarget|January 16, 2017
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]Laurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cell Cycle (Georgetown, Tex.)|February 16, 2006
Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entryYun Dai, Tracy E Hamm, Paul Dent, et al.
Oncology Signaling|February 12, 2019
NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Kinase inhibitors: look beyond the label on the bottlePaul Dent, Andrew Poklepovic, Laurence Booth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulationGirija Dasmahapatra, Nitin Yerram, Yun Dai, et al.
Cancer Research|January 20, 2007
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocationShuang Chen, Yun Dai, Hisashi Harada, et al.
Cancer Biology & Therapy|January 8, 2009
PI3K: A rational target for ovarian cancer therapy?Paul Dent, Steven Grant, Paul B Fisher, et al.
Cancer Biology & Therapy|December 17, 2009
Minting a new class of polo-like-kinase inhibitorsPaul Dent, David T Curiel, Steven Grant, et al.
Molecular Pharmacology|May 5, 2006
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanismNing Gao, Lora Kramer, Mohamed Rahmani, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 26, 2008
Approaches for monitoring signal transduction changes in normal and cancer cellsPaul Dent, Philip B Hylemon, Steven Grant, et al.
Pageof 40

Showing results (71-80 of 395) with videos related to

Sort By:
Pageof 40
Oncotarget|January 16, 2017
PDE5 inhibitors enhance the lethality of [pemetrexed + sorafenib]Laurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cell Cycle (Georgetown, Tex.)|February 16, 2006
Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entryYun Dai, Tracy E Hamm, Paul Dent, et al.
Oncology Signaling|February 12, 2019
NEDD4 over-expression regulates the afatinib resistant phenotype of NSCLC cellsLaurence Booth, Jane L Roberts, Andrew Poklepovic, et al.
Cancer Drug Resistance (Alhambra, Calif.)|May 18, 2022
Kinase inhibitors: look beyond the label on the bottlePaul Dent, Andrew Poklepovic, Laurence Booth, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Synergistic interactions between vorinostat and sorafenib in chronic myelogenous leukemia cells involve Mcl-1 and p21CIP1 down-regulationGirija Dasmahapatra, Nitin Yerram, Yun Dai, et al.
Cancer Research|January 20, 2007
Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocationShuang Chen, Yun Dai, Hisashi Harada, et al.
Cancer Biology & Therapy|January 8, 2009
PI3K: A rational target for ovarian cancer therapy?Paul Dent, Steven Grant, Paul B Fisher, et al.
Cancer Biology & Therapy|December 17, 2009
Minting a new class of polo-like-kinase inhibitorsPaul Dent, David T Curiel, Steven Grant, et al.
Molecular Pharmacology|May 5, 2006
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional mechanismNing Gao, Lora Kramer, Mohamed Rahmani, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 26, 2008
Approaches for monitoring signal transduction changes in normal and cancer cellsPaul Dent, Philip B Hylemon, Steven Grant, et al.
Pageof 40